144 related articles for article (PubMed ID: 33626044)
1. Renal function impairment in cervical cancer patients treated with cisplatin-based chemoradiation: A review of medical records in a Zimbabwean outpatient department.
Manyau PMC; Mabeka M; Mudzviti T; Kadzatsa W; Nyamhunga A
PLoS One; 2021; 16(2):e0245383. PubMed ID: 33626044
[TBL] [Abstract][Full Text] [Related]
2. Chemoradiotherapy treatment with gemcitabine improves renal function in locally advanced cervical cancer patients with renal dysfunction.
Alarcón-Barrios S; Luvián-Morales J; Castro-Eguiluz D; Delgadillo-González M; Lezcano-Velázquez BO; Arango-Bravo EA; Flores-Cisneros L; Aguiar Rosas S; Cetina-Pérez L
Curr Probl Cancer; 2024 Feb; 48():101041. PubMed ID: 37988902
[TBL] [Abstract][Full Text] [Related]
3. Assessment of renal function in routine care of people living with HIV on ART in a resource-limited setting in urban Zambia.
Deckert A; Neuhann F; Klose C; Bruckner T; Beiersmann C; Haloka J; Nsofwa M; Banda G; Brune M; Reutter H; Rothenbacher D; Zeier M
PLoS One; 2017; 12(9):e0184766. PubMed ID: 28931037
[TBL] [Abstract][Full Text] [Related]
4. Chemoradiotherapy completion and neutropenia risk in HIV patients with cervical cancer.
Vendrell I; Ferreira AR; Abrunhosa-Branquinho AN; Semedo PM; Pulido CF; Jorge M; Pina MF; Pinto C; Costa L
Medicine (Baltimore); 2018 Jul; 97(30):e11592. PubMed ID: 30045290
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
[TBL] [Abstract][Full Text] [Related]
6. Assessing renal impairment in treatment-naïve adolescents living with HIV commencing antiretroviral therapy in Zimbabwe.
Byers BW; Drak D; Shamu T; Chimbetete C; Dahwa R; Gracey DM
AIDS; 2023 Apr; 37(5):789-794. PubMed ID: 36728249
[TBL] [Abstract][Full Text] [Related]
7. Renal outcomes after up to 8 years of tenofovir exposure in HIV-HBV-coinfected patients.
Boyd A; Miailhes P; Lascoux-Combe C; Rougier H; Girard PM; Plaisier E; Lacombe K
Antivir Ther; 2017; 22(1):31-42. PubMed ID: 27553871
[TBL] [Abstract][Full Text] [Related]
8. Renal abnormalities among HIV-infected, antiretroviral naive children, Harare, Zimbabwe: a cross-sectional study.
Dondo V; Mujuru HA; Nathoo KJ; Chirehwa M; Mufandaedza Z
BMC Pediatr; 2013 May; 13():75. PubMed ID: 23663553
[TBL] [Abstract][Full Text] [Related]
9. Renal function and associated mortality risk in adults commencing HIV antiretroviral therapy in Zimbabwe.
Drak D; Shamu T; Heron JE; Chimbetete C; Dahwa R; Gracey DM
AIDS; 2022 Apr; 36(5):631-636. PubMed ID: 34923518
[TBL] [Abstract][Full Text] [Related]
10. Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi.
Chikwapulo B; Ngwira B; Sagno JB; Evans R
Int J STD AIDS; 2018 Jun; 29(7):650-657. PubMed ID: 29334883
[TBL] [Abstract][Full Text] [Related]
11. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
Nishijima T; Kawasaki Y; Tanaka N; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Gatanaga H; Oka S
AIDS; 2014 Aug; 28(13):1903-10. PubMed ID: 25259702
[TBL] [Abstract][Full Text] [Related]
12. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Hwang JH; Lim MC; Seo SS; Kang S; Park SY; Kim JY
Arch Gynecol Obstet; 2012 Jun; 285(6):1685-93. PubMed ID: 22173823
[TBL] [Abstract][Full Text] [Related]
14. Age-corrected hearing loss after chemoradiation in cervical cancer patients.
Marnitz S; Schermeyer L; Dommerich S; Köhler C; Olze H; Budach V; Martus P
Strahlenther Onkol; 2018 Nov; 194(11):1039-1048. PubMed ID: 30120496
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
[TBL] [Abstract][Full Text] [Related]
16. Daily low-dose cisplatin-based concurrent chemoradiotherapy in patients with uterine cervical cancer with emphasis on elderly patients: a phase 2 trial.
Mitsuhashi A; Uno T; Usui H; Nishikimi K; Yamamoto N; Watanabe M; Tate S; Hirashiki K; Kato K; Yamazawa K; Shozu M
Int J Gynecol Cancer; 2013 Oct; 23(8):1453-8. PubMed ID: 23266648
[TBL] [Abstract][Full Text] [Related]
17. Predictors of renal impairment and proteinuria after commencement of antiretroviral therapy in a Zimbabwean HIV cohort.
Drak D; Heron JE; Shamu T; Chimbetete C; Dahwa R; Gracey DM
HIV Med; 2022 Oct; 23(9):1002-1006. PubMed ID: 35394105
[TBL] [Abstract][Full Text] [Related]
18. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML
J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.
Kagabu M; Shoji T; Murakami K; Omi H; Honda T; Miura F; Yokoyama Y; Tokunaga H; Takano T; Ohta T; Shimizu D; Sato N; Soeda S; Watanabe T; Yamada H; Mizunuma H; Yaegashi N; Nagase S; Tase T; Sugiyama T
Int J Clin Oncol; 2016 Aug; 21(4):735-740. PubMed ID: 26782958
[TBL] [Abstract][Full Text] [Related]
20. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
Knijnenburg SL; Mulder RL; Schouten-Van Meeteren AY; Bökenkamp A; Blufpand H; van Dulmen-den Broeder E; Veening MA; Kremer LC; Jaspers MW
Cochrane Database Syst Rev; 2013 Oct; (10):CD008944. PubMed ID: 24101439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
